OncoMatch/Clinical Trials/NCT06536049
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Is NCT06536049 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Epcoritamab and Ibrutinib for recurrent diffuse large b-cell lymphoma.
Treatment: Epcoritamab · Ibrutinib — This phase Ib/II trial evaluates the safety, optimal dose, and efficacy of the combination of epcoritamab and ibrutinib in treating patients with aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or responded to previous treatment (refractory). Epcoritamab, a bispecific antibody, binds to two different types of receptors (proteins present on the cell surface) at the same time. The two receptors that epcoritamab binds to are called CD3 and CD20. CD3 is found on T cells, which are important cells of the immune system that help fight cancer and infections. CD20 is found on the surface of most types of aggressive B-cell non-Hodgkin lymphoma cells. By binding to both CD3 and CD20, epcoritamab brings the two cells close together so the T cells can fight and kill the lymphoma B cells. Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, binds to a protein on B cells, a type of white blood cell from which the lymphoma developed. By doing this it decreases the ability of the lymphoma B cells to survive and grow. Ibrutinib may also improve the health (or fitness) of T cells thus making epcoritamab safer and/or more effective.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 overexpression (positive by flow cytometry and/or immunohistochemistry)
CD20+ B-cell non-Hodgkin lymphoma subtypes (note, documentation of CD20 positivity by flow cytometry and/or immunohistochemistry is based on any representative pathology report)
Allowed: MYC rearrangement
High-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements (double-hit or triple-hit lymphoma)
Allowed: BCL2 rearrangement
High-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements (double-hit or triple-hit lymphoma)
Allowed: BCL6 rearrangement
High-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements (double-hit or triple-hit lymphoma)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anthracycline — in combination with an anti-CD20 monoclonal antibody
received prior treatment with an anthracycline in combination with an anti-CD20 monoclonal antibody
Cannot have received: bispecific antibody targeting CD3 and CD20
Prior therapy with a bispecific antibody targeting CD3 and CD20
Lab requirements
Blood counts
ANC ≥ 1,000/mcL; Platelet count ≥ 75,000/mcL (≥ 50,000/mcL if bone marrow involvement and/or splenomegaly); Hemoglobin ≥ 8 g/dL; Transfusion and/or growth factor support within 7 days (or 14 days for long-acting growth factors) of enrollment to meet these requirements is not permitted
Kidney function
Creatinine clearance > 45 mL/min calculated by Cockcroft-Gault. Patients on dialysis are not eligible
Liver function
Total bilirubin ≤ 1.5 x ULN (unless due to Gilbert's disease or hemolysis in which case bilirubin must be < 3 x ULN); AST < 3 x ULN; ALT < 3 x ULN
ANC ≥ 1,000/mcL; Platelet count ≥ 75,000/mcL (≥ 50,000/mcL if bone marrow involvement and/or splenomegaly); Hemoglobin ≥ 8 g/dL; Total bilirubin ≤ 1.5 x ULN (unless due to Gilbert's disease or hemolysis in which case bilirubin must be < 3 x ULN); AST < 3 x ULN; ALT < 3 x ULN; Creatinine clearance > 45 mL/min calculated by Cockcroft-Gault. Patients on dialysis are not eligible
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Minnesota/Masonic Cancer Center · Minneapolis, Minnesota
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify